Spotlights Key Drivers of Growth for Upcoming Decade, Including Progress on New Launches and Forthcoming Clinical and Regulatory Milestones across Product PipelineAnnounces $5 Billion Accelerated Share Repurchase Agreement to Be Executed During the First QuarterProvides 2022 Total Revenue and Non-GAAP EPS GuidanceRe.